SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo

🎯 Drug Targets

Browse 2 drug targets with druggability analysis, composite scores, and clinical context

2
Targets
2
High Druggability
0.67
Avg Score
15
Target Classes
Druggability Distribution
High: 2Medium: 0Low: 0Unknown: 0
Avg druggability score: 0.765
Clinical Pipeline
Approved: 0Phase III: 0Phase II: 1Phase I: 0Preclinical: 1
Total compounds: 5 · Approved: 0
Class All Classes Enzyme (35) Signaling Protein (25) Structural Protein (17) Protein (16) Gpcr (13) Ion Channel (12) Transcription Factor (11) Receptor (11) Ligand (10) Transporter (8) Epigenetic Regulator (8) Kinase (7) Protease (4) Other (4) Chaperone (4)
Druggability All Druggability Low (100) Medium (62) High (14) Undruggable (6) other (3)
Sort Score Druggability Gene A-Z Market Price
Filtered by: class=epigenetic_regulator, druggability=High — 2 results
BRD4 Bromodomain-containing protein 4
Epigenetic Regulator High Druggability
Score
0.72
Drug.
0.73
Safety
0.62
Drugs
2
Hyps
1
Papers
35
BRD4 inhibition reduces neuroinflammatory super-enhancer activity while biased BRD4 modulators can selectively restore neuroprotective gene expression
SIRT1 NAD-dependent protein deacetylase sirtuin-1 Phase 2
Epigenetic Regulator High Druggability
Score
0.63
Drug.
0.80
Safety
0.73
Drugs
3
Hyps
2
Papers
44
SIRT1 activation via NAD+ precursors or allosteric activators deacetylates tau (reducing aggregation), enhances mitophagy, and restores circadian gene expression
Exchange | Dashboard